Marketdash
Back to News

GRI Bio's Experimental Drug Shows Lung Function Improvements in Pulmonary Fibrosis Trial

MarketDash Editorial Team
17 hours ago
GRI Bio reported encouraging Phase 2a trial results for its experimental treatment targeting idiopathic pulmonary fibrosis, a progressive lung disease that causes scarring and breathing difficulties with no known cure.

GRI Bio, Inc. (GRI) delivered some genuinely interesting data Wednesday from a Phase 2a trial testing GRI-0621 as a treatment for idiopathic pulmonary fibrosis. If you're wondering what that is, think of it as a cruel disease where your lung tissue gradually thickens and scars for reasons doctors still can't explain, making every breath progressively harder.

The trial hit its primary endpoint and secondary endpoints, showing that patients tolerated the drug well over 12 weeks. That's consistent with earlier studies involving more than 1,700 people treated for up to a year, which is reassuring when you're trying to prove a drug won't cause problems down the road.

What Went Wrong (Or Rather, What Didn't)

Safety-wise, things looked pretty clean. The most common side effects were dry skin, dry lips, and muscle and joint pain—annoying, sure, but not exactly alarming. More interesting is what didn't happen: zero cases of cough in the GRI-0621 group compared to 25% in the placebo group. And diarrhea showed up in only 13% of treated patients versus 33% taking placebo. That's actually better than doing nothing, which is a nice problem to have.

Worth noting that 80% of patients were already taking pirfenidone or nintedanib, the current standard treatments, so this drug was being tested on top of existing therapies.

The Science Gets Interesting

Here's where things get compelling. Patients on GRI-0621 showed improvements in serum biomarkers related to collagen turnover, suggesting the drug might actually be resolving fibrosis rather than just slowing it down. The type VI collagen remodeling rate shifted from fibrogenic (meaning continued scarring, at +10%) in placebo patients to fibrolytic (meaning resolution of scarring, at -7%) in treated patients. That's a meaningful swing in the right direction.

The drug also significantly reduced DLK1, a gene involved in lung cell regeneration and repair. Think of it as flipping a switch that helps the lung's basement membrane repair itself—a critical step in actually fixing the damage rather than just managing symptoms.

Inflammation and Lung Function Improvements

GRI-0621 reduced activity of neutrophils and macrophages, immune cells that get overactive in IPF and contribute to disease progression. The drug also downregulated genes associated with fibrosis, disease progression, and mortality compared to placebo.

Now for the lung function numbers: forced vital capacity (FVC), which measures how much air you can forcefully exhale, increased by 99 ml in the GRI-0621 group after adjusting for placebo. In patients taking both GRI-0621 and standard care, that jumped to 139 ml compared to placebo plus standard care. About 39% of treated patients saw their FVC increase at 12 weeks, while 80% of placebo patients experienced declining lung function.

GRI Price Action: GRI Bio shares dropped 7.45% to $1.11 in premarket trading Wednesday, hovering near the 52-week low of $1.10.

Back to News

GRI Bio's Experimental Drug Shows Lung Function Improvements in Pulmonary Fibrosis Trial

MarketDash Editorial Team
17 hours ago
GRI Bio reported encouraging Phase 2a trial results for its experimental treatment targeting idiopathic pulmonary fibrosis, a progressive lung disease that causes scarring and breathing difficulties with no known cure.

GRI Bio, Inc. (GRI) delivered some genuinely interesting data Wednesday from a Phase 2a trial testing GRI-0621 as a treatment for idiopathic pulmonary fibrosis. If you're wondering what that is, think of it as a cruel disease where your lung tissue gradually thickens and scars for reasons doctors still can't explain, making every breath progressively harder.

The trial hit its primary endpoint and secondary endpoints, showing that patients tolerated the drug well over 12 weeks. That's consistent with earlier studies involving more than 1,700 people treated for up to a year, which is reassuring when you're trying to prove a drug won't cause problems down the road.

What Went Wrong (Or Rather, What Didn't)

Safety-wise, things looked pretty clean. The most common side effects were dry skin, dry lips, and muscle and joint pain—annoying, sure, but not exactly alarming. More interesting is what didn't happen: zero cases of cough in the GRI-0621 group compared to 25% in the placebo group. And diarrhea showed up in only 13% of treated patients versus 33% taking placebo. That's actually better than doing nothing, which is a nice problem to have.

Worth noting that 80% of patients were already taking pirfenidone or nintedanib, the current standard treatments, so this drug was being tested on top of existing therapies.

The Science Gets Interesting

Here's where things get compelling. Patients on GRI-0621 showed improvements in serum biomarkers related to collagen turnover, suggesting the drug might actually be resolving fibrosis rather than just slowing it down. The type VI collagen remodeling rate shifted from fibrogenic (meaning continued scarring, at +10%) in placebo patients to fibrolytic (meaning resolution of scarring, at -7%) in treated patients. That's a meaningful swing in the right direction.

The drug also significantly reduced DLK1, a gene involved in lung cell regeneration and repair. Think of it as flipping a switch that helps the lung's basement membrane repair itself—a critical step in actually fixing the damage rather than just managing symptoms.

Inflammation and Lung Function Improvements

GRI-0621 reduced activity of neutrophils and macrophages, immune cells that get overactive in IPF and contribute to disease progression. The drug also downregulated genes associated with fibrosis, disease progression, and mortality compared to placebo.

Now for the lung function numbers: forced vital capacity (FVC), which measures how much air you can forcefully exhale, increased by 99 ml in the GRI-0621 group after adjusting for placebo. In patients taking both GRI-0621 and standard care, that jumped to 139 ml compared to placebo plus standard care. About 39% of treated patients saw their FVC increase at 12 weeks, while 80% of placebo patients experienced declining lung function.

GRI Price Action: GRI Bio shares dropped 7.45% to $1.11 in premarket trading Wednesday, hovering near the 52-week low of $1.10.